Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments, Significant Contracts and Contingencies (Tables)

Commitments, Significant Contracts and Contingencies (Tables)

3 Months Ended

Nov. 30, 2023

Commitments, Significant Contracts and Contingencies

Schedule of operating lease liabilities

		November 30, 2023				August 31, 2023
Right of use assets - operating leases		$	167,446			$	52,444
Amortization			(10,881	)			(41,564	)
Extension-related remeasurement			-				156,566
Total lease assets		$	156,565			$	167,446

Liabilities:		$	163,967			$	49,988
Lease payments			(8,963	)			(44,814	)
Interest accretion			67				2,227
Extension-related remeasurement			-				156,566
Total lease liabilities		$	155,071			$	163,967

Operating lease cost		$	156,565			$	167,446
Operating cash flows for lease		$	8,963			$	44,814
Remaining lease term		4.92 Years				5.17 Years
Discount rate			7.25	%			7.25	%

Schedule of maturities of operating lease liabilities

2024			26,878
2025			37,094
2026			37,345
2027			38,642
2028			38,901
2029			6,483
Thereafter			-
Total lease payments			185,343
Less: imputed interest			(30,272	)
Present value of operating lease liabilities			155,071
Less: current obligations under leases			(25,554	)
Total			129,517